BioNTech’s $1 Billion Buyback Can’t Mask the Pain of a Post-Pandemic Hangover

The numbers tell a stark story. BioNTech’s first-quarter revenue slumped to €118.1 million, down roughly 31% from €182.8 million a year earlier, as the COVID-19 vaccine franchise continues its steady decline. The shortfall was roughly 30% below analyst expectations, underscoring just how quickly the pandemic windfall has evaporated.

The net loss widened to $622.3 million from $486.5 million in the prior-year period, driven by a surge in research spending. The company ploughed €557 million into R&D, up from €525.6 million, with the bulk of that cash flowing into immuno-oncology programmes such as Pumitamig and Gotistobart, as well as integrating the 2025 acquisitions of BioNTech China and CureVac.

Yet for all the red ink, BioNTech’s balance sheet remains formidable. The company ended the first quarter with roughly €16.8 billion in cash and securities — a war chest that gives it ample room to fund its transformation into a pure-play oncology powerhouse.

A $1 Billion Vote of Confidence

On 7 May, the Mainz-based group formally launched a new share buyback programme of up to $1 billion, to run through May 2027. The move is designed to shore up investor confidence during a period of profound upheaval. The stock has lost roughly 10% over the past week alone, slipping to €79.15 and falling below its 50-day moving average. It now trades about 22% below its 52-week high.

Should investors sell immediately? Or is it worth buying BioNTech?

The buyback comes as the company prepares for a seismic shift in leadership. At the annual general meeting on 15 May, founders Ugur Sahin and Özlem Türeci will announce their departure from management by the end of 2026. They will move to helm a new venture, with BioNTech contributing technology in exchange for a minority stake. To smooth the transition, the supervisory board will expand from six to eight members, adding two specialists in oncology and clinical development.

Pipeline Pressure Points

The clock is ticking on BioNTech’s cancer pivot. The company has six late-stage data readouts scheduled for 2026, spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. The next major catalyst comes at the end of May, when BioNTech presents Phase 2 data from the ROSETTA-Lung-02 study at the ASCO congress, pitting its candidate Pumitamig directly against the established standard, Pembrolizumab.

Gotistobart, a CTLA-4 antibody developed in partnership with OncoC4, has already shown a clinically meaningful survival benefit in squamous cell lung cancer at the European Lung Cancer Congress in March. Interim Phase 3 data are expected later this year.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Meanwhile, the COVID-19 business continues to shrink. BioNTech and Pfizer were forced to halt a large US study of an updated vaccine targeting healthy adults aged 50 to 64 — a demographic that still lacks a fully FDA-approved COVID shot. The companies cited insufficient enrolment rather than safety concerns, but the timing is awkward: the FDA’s vaccine advisory committee meets in May and had hoped to review the data ahead of the autumn season.

Management has maintained its full-year 2026 revenue forecast of between $2.3 billion and $2.6 billion, down from $2.9 billion in 2025. Whether the pipeline can justify the billions already spent will become clearer by year-end, with the Gotistobart interim data serving as the next hard milestone. For now, BioNTech is betting that its cash pile and buyback can keep shareholders patient while the science catches up.

Ad

BioNTech Stock: New Analysis - 8 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69290553 |